Company profile for Vaxxas

NEW Drugs in Dev: 9
PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Vaxxas is a privately held biotechnology company focused on enhancing the performance of existing and next-generation vaccines with its proprietary HD-MAP technology platform, which uses an ultra-high density array of projections – invisible to the naked human eye – applied to the skin to rapidly deliver vaccine to the abundant immune cells immediately below the skin surface. This approach can enhance efficiency and effect...
Vaxxas is a privately held biotechnology company focused on enhancing the performance of existing and next-generation vaccines with its proprietary HD-MAP technology platform, which uses an ultra-high density array of projections – invisible to the naked human eye – applied to the skin to rapidly deliver vaccine to the abundant immune cells immediately below the skin surface. This approach can enhance efficiency and effectiveness of immune response.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
47 Thorndike Street, Suite B1-1 Cambridge, Massachusetts 02141 USA
Telephone
Telephone
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/12/14/3205032/0/en/Vaxxas-Secures-TGA-Licence-to-Manufacture-Therapeutic-Goods.html

GLOBENEWSWIRE
14 Dec 2025

https://www.globenewswire.com/news-release/2025/11/10/3184484/0/en/Vaxxas-Appoints-Veteran-Vaccine-Leader-to-Board-as-Company-Advances-Needle-Free-Vaccine-Patch-Towards-Market.html

GLOBENEWSWIRE
10 Nov 2025

https://www.prnewswire.com/news-releases/obviohealth-and-vaxxas-sign-multi-year-agreement-to-power-needle-free-vaccination-technology-trials-with-obviogo-302595623.html

PR NEWSWIRE
28 Oct 2025

https://www.globenewswire.com/news-release/2025/08/25/3138224/0/en/Vaxxas-secures-A-90-million-in-funding-to-commercialise-needle-free-vaccination-delivery-technology.html

GLOBENEWSWIRE
25 Aug 2025

https://www.businesswire.com/news/home/20250318170088/en/Vaxxas-Secures-New-U.S.-Patent-For-its-Needle-Free-Vaccination-Manufacturing-Technology

BUSINESSWIRE
18 Mar 2025

https://www.businesswire.com/news/home/20250304287478/en

BUSINESSWIRE
04 Mar 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty